Hypoglycaemia downregulates endotoxin-induced production of tumour necrosis factor-α, but does not affect IL-1β, IL-6, or IL-10

Cytokine

Volumn 22, Issue 3-4, 2003, Pages 71-76

  De Galan, B E ^a   Netea, M G ^a   Smits, P ^a   Van Der Meer, J W M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diabetes mellitus; Humans; Hypoglycaemia; Insulin; TNF

Indexed keywords

ADRENALIN; CYTOKINE; ENDOTOXIN; GLUCOSE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD; CELL CULTURE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; FEMALE; GLUCOSE CLAMP TECHNIQUE; HORMONE RESPONSE; HUMAN; HUMAN CELL; HYPERINSULINEMIA; HYPOGLYCEMIA; IMMUNOMODULATION; IN VITRO STUDY; INFLAMMATION; MALE; METABOLISM; PRIORITY JOURNAL; PROTEIN DETERMINATION;

EID: 0038384886     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-4666(03)00113-3     Document Type: Article

References (29)

1. Van der Poll T., De Waal Malefyt R., Coyle S.M., Lowry S.F. Antiinflammatory cytokine responses during clinical sepsis and experimental endotoxemia: sequential measurements of plasma soluble interleukin (IL)-1 receptor type II, IL-10, and IL-13. J Infect Dis. 175:1997;118-122.
2. Drenth J.P., Van Uum S.H., Van Deuren M., Pesman G.J., Van der Ven Jongekrijg J., Van der Meer J.W. Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol. 79:1995;1497-1503.
3. Roumen R.M., Hendriks T., Van der Ven-Jongekrijg J., Nieuwenhuijzen G.A., Sauerwein R.W., Van der Meer J.W., et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg. 218:1993;769-776.
4. Lahat N., Zlotnick A.Y., Shtiller R., Bar I., Merin G. Serum levels of IL-1, IL-6 and tumour necrosis factors in patients undergoing coronary artery bypass grafts or cholecystectomy. Clin Exp Immunol. 89:1992;255-260.
5. Van Deuren M., Twickler T.B., De Waal Malefyt M.C., Van Beem H., Van der Ven-Jongekrijg J., Verschueren C.M.M., et al. Elective orthopedic surgery, a model for the study of cytokine activation and regulation. Cytokine. 10:1998;897-903.
6. Schmand J.F., Ayala A., Chaudry I.H. Effects of trauma, duration of hypotension, and resuscitation regimen on cellular immunity after hemorrhagic shock. Crit Care Med. 22:1994;1076-1083.
7. Van der Poll T., Calvano S.E., Kumar A., Coyle S.M., Lowry S.F. Epinephrine attenuates down-regulation of monocyte tumor necrosis factor receptors during human endotoxemia. J Leukoc Biol. 61:1997;156-160.
8. De Waal M.R., Haanen J., Spits H., Roncarolo M.G., Te Velde A., Figdor C., et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 174:1991;915-924.
9. Bogdan C., Paik J., Vodovotz Y., Nathan C. Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10. J Biol Chem. 267:1992;23301-23308.
10. Van der Poll T., Lowry S.F. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factor-alpha and IL-10. Am J Physiol. 273:1997;R1885-R1890.
11. Severn A., Rapson N.T., Hunter C.A., Liew F.Y. Regulation of tumor necrosis factor production by adrenaline and beta-adrenergic agonists. J Immunol. 148:1992;3441-3445.
12. Van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. J Clin Invest. 97:1996;713-719.
13. Ziegler Heitbrock H.W. Molecular mechanism in tolerance to lipopolysaccharide. J Inflamm. 45:1995;13-26.
14. Zellweger R., Zhu X.H., Wichmann M.W., Ayala A., DeMaso C.M., Chaudry I.H. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J Immunol. 157:1996;5748-5754.
15. Lundy J., Ford C.M. Surgery, trauma and immune suppression. Evolving the mechanism. Ann Surg. 197:1983;434-438.
16. Mitrakou A., Ryan C., Veneman T., Mokan M., Jenssen T., Kiss I., et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol. 260:1991;E67-E74.
17. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:1993;977-986.
18. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 352:1998;837-853.
19. Morohoshi M., Fujisawa K., Uchimura I., Numano F. Glucose-dependent interleukin 6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes. 45:1996;954-959.
20. Hancu N., Netea M.G., Baciu I. High glucose concentrations increase the tumor necrosis factor-alpha production capacity by human peripheral blood mononuclear cells. Rom J Physiol. 35:1998;325-330.
21. Soop M., Duxbury H., Agwunobi A.O., Gibson J.M., Hopkins S.J., Childs C., et al. Euglycemic hyperinsulinemia augments the cytokine and endocrine responses to endotoxin in humans. Am J Physiol Endocrinol Metab. 282:2002;E1276-E1285.
22. Kiecolt Glaser J.K., Marucha P.T., Malarkey W.B., Mercado A.M., Glaser R. Slowing of wound healing by psychological stress. Lancet. 346:1995;1194-1196.
23. Granowitz E.V., Porat R., Mier J.W., Orencole S.F., Kaplanski G., Lynch E.A., et al. Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol. 151:1993;1637-1645.
24. Cryer P.E. Banting Lecture. Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 43:1994;1378-1389.
25. Ohno Y., Aoki N., Nishimura A. In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 77:1993;1072-1077.
26. Giordano C., Panto F., Caruso C., Modica M.A., Zambito A.M., Sapienza N., et al. Interleukin 2 and soluble interleukin 2-receptor secretion defect in vitro in newly diagnosed type I diabetic patients. Diabetes. 38:1989;310-315.
27. De Galan B.E., Tack C.J., Lenders J.W., Pasman J.W., Elving L.D., Russel F.G., et al. Theophylline improves hypoglycemia unawareness in type 1 diabetes. Diabetes. 51:2002;790-796.
28. Van Deuren M., Van der Ven-Jongekrijg J., Keuter M., Demacker P.N., Van der Meer J.W.M. Cytokine production in whole blood cultures. J Int Fed Clin Chem. 5:1993;216-219.
29. Van der Hoorn F.A., Boomsma F., Man in 't Veld A.J., Schalekamp M.A. Determination of catecholamines in human plasma by high-performance liquid chromatography: comparison between a new method with fluorescence detection and an established method with electrochemical detection. J Chromatogr. 487:1989;17-28.